As of September 30, 2022, cash, cash equivalents and investments in marketable securities totaled $305.1M. The company continues to expect this will fund its planned operations into the fourth quarter of 2024. "Over the third quarter, we have continued to focus on execution of our Phase 1/2 CEDAR clinical trial of nula-cel for sickle cell disease. We are pleased to have recently dosed our first patient with nula-cel, marking the first time an investigational therapy designed to correct a genetic mutation has been administered to a patient. We continue to enroll patients in CEDAR and look forward to reporting initial clinical proof-of-concept data in mid-2023," said Josh Lehrer, CEO. "Additionally, we are excited to partner with WuXi Advanced Therapies to support the manufacturing of nula-cel as we scale and work to develop and deliver our potentially curative therapy for sickle cell disease to those who desperately need it. Finally, we are thrilled to welcome Darren Hart to the Graphite Bio team, whose expertise in overseeing clinical trials, including those for sickle cell disease, will play a pivotal role in bringing our next-generation therapies to patients."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRPH:
